360 related articles for article (PubMed ID: 34771535)
41. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.
Ponzoni M; Issa S; Batchelor TT; Rubenstein JL
Ann Oncol; 2014 Feb; 25(2):316-22. PubMed ID: 24265352
[TBL] [Abstract][Full Text] [Related]
42. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
43. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
44. CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
Karschnia P; Blobner J; Teske N; Schöberl F; Fitzinger E; Dreyling M; Tonn JC; Thon N; Subklewe M; von Baumgarten L
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065471
[TBL] [Abstract][Full Text] [Related]
45. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
Skånland SS; Mato AR
Blood Adv; 2021 Jan; 5(1):334-343. PubMed ID: 33570649
[TBL] [Abstract][Full Text] [Related]
46. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
47. Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse.
Ghione P; Lewis KL; Bobillo S; Nayak L; Schorb E; Nichelli L; Ng A; Savage KJ; McKay P; Nastoupil L; Soussain C; Cwynarski K
Hematol Oncol; 2023 Jun; ():. PubMed ID: 37381737
[TBL] [Abstract][Full Text] [Related]
48. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
49. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Muqbil I; Chaker M; Aboukameel A; Mohammad RM; Azmi AS; Ramchandren R
Heliyon; 2019 Aug; 5(8):e02290. PubMed ID: 31508518
[TBL] [Abstract][Full Text] [Related]
50. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
[TBL] [Abstract][Full Text] [Related]
51. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
52. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
53. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.
George B; Chowdhury SM; Hart A; Sircar A; Singh SK; Nath UK; Mamgain M; Singhal NK; Sehgal L; Jain N
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455989
[TBL] [Abstract][Full Text] [Related]
54. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma.
Alcantara M; Fuentealba J; Soussain C
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680209
[TBL] [Abstract][Full Text] [Related]
55. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
56. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
57. Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.
Takashima Y; Hayano A; Yamanaka R
Clin Cancer Res; 2020 Jun; 26(11):2754-2766. PubMed ID: 32108030
[TBL] [Abstract][Full Text] [Related]
58. How we treat primary central nervous system lymphoma.
Calimeri T; Steffanoni S; Gagliardi F; Chiara A; Ferreri AJM
ESMO Open; 2021 Aug; 6(4):100213. PubMed ID: 34271311
[TBL] [Abstract][Full Text] [Related]
59. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
Xia B; Qu F; Yuan T; Zhang Y
Oncol Lett; 2015 Dec; 10(6):3339-3344. PubMed ID: 26788133
[TBL] [Abstract][Full Text] [Related]
60. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]